Revolution Medicines, Inc. (RVMD)
209.23
-0.64
(-0.30%)
USD |
NASDAQ |
Sep 02, 16:00
210.42
+1.19
(+0.57%)
After-Hours: 06:49
Revolution Medicines Research and Development Expense (TTM) : 1.287B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.287B |
| March 31, 2026 | 1.117B |
| December 31, 2025 | 978.68M |
| September 30, 2025 | 872.17M |
| June 30, 2025 | 761.84M |
| March 31, 2025 | 672.76M |
| December 31, 2024 | 585.18M |
| September 30, 2024 | 545.96M |
| June 30, 2024 | 502.30M |
| March 31, 2024 | 465.77M |
| December 31, 2023 | 417.03M |
| September 30, 2023 | 334.88M |
| June 30, 2023 | 296.87M |
| March 31, 2023 | 260.18M |
| Date | Value |
|---|---|
| December 31, 2022 | 248.03M |
| September 30, 2022 | 235.92M |
| June 30, 2022 | 213.14M |
| March 31, 2022 | 198.20M |
| December 31, 2021 | 182.80M |
| September 30, 2021 | 166.26M |
| June 30, 2021 | 154.79M |
| March 31, 2021 | 141.94M |
| December 31, 2020 | 128.57M |
| September 30, 2020 | 120.00M |
| June 30, 2020 | 108.15M |
| March 31, 2020 | 95.44M |
| December 31, 2019 | 89.28M |
| September 30, 2019 | 79.97M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Tango Therapeutics, Inc. | 131.73M |
| Erasca, Inc. | 108.88M |
| Moderna, Inc. | 2.635B |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Intellia Therapeutics, Inc. | 337.63M |